Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, Ochkur SI, Jacobsen EA, Hou YX, Andrews PE, Colby TV, Lee NA, Lee JJ.

Urol Oncol. 2014 Jan;32(1):45.e23-30. doi: 10.1016/j.urolonc.2013.06.008.

2.

Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.

Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S.

Ultrastruct Pathol. 2013 Feb;37(1):56-61. doi: 10.3109/01913123.2012.728688.

PMID:
23383616
3.

Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.

Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N.

J Urol. 2009 Apr;181(4):1894-900. doi: 10.1016/j.juro.2008.11.090.

PMID:
19237175
4.

Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer.

Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, Sato N, Tsukamoto T.

Clin Cancer Res. 2006 Aug 1;12(15):4641-4.

6.

Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.

Lebret T, Becette V, Hervé JM, Molinié V, Barré P, Lugagne PM, Gentille A, Baglin AC, Botto H.

Eur Urol. 2000 Jun;37(6):654-9.

PMID:
10828663
8.

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.

Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y.

Eur Urol. 2009 Jun;55(6):1386-95. doi: 10.1016/j.eururo.2009.01.040.

PMID:
19193487
9.

Soluble urinary CD14 after intravesical bacille Calmette-Guérin immunotherapy for carcinoma in situ.

Jackson AM, Lien E, Alexandroff AB, Prescott S, Espevik T, James K, Selby PJ, Sundan A.

Br J Urol. 1997 Nov;80(5):766-71.

PMID:
9393300
10.

Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K.

Clin Infect Dis. 2000 Sep;31 Suppl 3:S91-3. Review.

PMID:
11010831
11.

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP.

J Urol. 2012 Mar;187(3):862-7. doi: 10.1016/j.juro.2011.10.144.

12.

Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.

Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.

J Urol. 2006 Aug;176(2):482-5.

PMID:
16813873
13.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.

J Urol. 2000 Apr;163(4):1124-9.

PMID:
10737480
14.
15.

[Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].

Yamada Y, Hara I, Kumano M, Furukawa J, Yamanaka K, Kamidono S.

Hinyokika Kiyo. 2005 Aug;51(8):539-43. Japanese.

PMID:
16164270
16.

Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, Kerckhaert JA, Schreinemachers LM, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruijne FM, Ruitenberg EJ.

Cancer Immunol Immunother. 1989;28(4):287-95.

PMID:
2784716
18.
19.
20.

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H.

Urol Oncol. 2013 Aug;31(6):849-56. doi: 10.1016/j.urolonc.2011.06.004.

PMID:
21782482
Items per page

Supplemental Content

Support Center